• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·France·Technology·EQS.PA
Share

Equasens Societe anonyme Stocks

€ 29.65Last Updated 23.10.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

€ 482.42M

€ 29.65
Key Takeaways

Risk factor

Limited trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Equasens S.A., established in 1996 and headquartered in Villers-les-Nancy, France, delivers a diverse portfolio of information technology solutions tailored for the European healthcare industry. The company primarily equips pharmacies and their networks with advanced management systems, including LGPI global services and OffiCentral. Pharmacists leverage a comprehensive suite of tools designed to streamline daily business operations, such as OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker. To foster stronger customer relationships and engagement, Equasens provides innovative solutions like OffiTag, OffiTouch, OffiMédia, OffiConnect, alongside automation systems and loyalty program management. Beyond operational software, the company offers analytical insights through its My Pilot tool and professional development opportunities via OffiLearning, an e-learning platform. A key area of focus is patient support, with offerings spanning compliance monitoring software, Multimeds, Automeds, OffiTéléconsult, and essential pharmaceutical and shared medical record services. The company's specialized systems include ULTIMATE, which combines efficient pharmacy administration with enhanced patient care, and FARMACLICK, a protocol facilitating communication between pharmacies and wholesale distributors (the latter also served by DIFARM). Additional retail management tools comprise PHARE and the SOPHIA pharmacy application, complemented by OffiMédia POS displays. Equasens also addresses specific health needs, such as chronic renal failure management with eNephro, and simplifies the administration of patient education programs through TPE Pilot. Further extending its reach across the healthcare sector, Equasens offers various dedicated solutions like NOVIACARE, CARELIB (for home and nursing home care), KAPELSE, TITAN, ANTHADINE software, the MOBISOINS mobile tool, MICROSOINS for in-home nursing care, and LOGICLIC. For holistic patient journey oversight, the AXIGATE solutions and CHORUS platform are available. Supplementary services include medical telesecretarial assistance for healthcare professionals and equipment lease financing options. Equasens S.A. functions as a subsidiary of Marque Verte Sante.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, underpriced o

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of EQS.PA is 55.6 and suggests 87.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.10.2026 16:01

Highlights in Small-Cap Stocks: The Merck Deal, the Success of a Hair Loss Pill, and Braze's "Wow Factor"

24.10.2026 13:01

AI investors are already on the brink, a “French kiss” for the euro, and hackers at the gates

24.10.2026 05:04

Hedge funds have ramped up their bets against the euro to a 2020 high

24.10.2026 04:46

France Avoided a Downgrade by Moody’s After a Week of Crisis

24.10.2026 04:37

A key Novartis drug failed to meet expectations. The stock price fell

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026